search
Back to results

Improving Hallucinations by Targeting the rSTS With tES

Primary Purpose

Hallucinations, Auditory, Psychosis

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Transcranial Electrical Stimulation
Sponsored by
Beth Israel Deaconess Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hallucinations, Auditory focused on measuring Transcranial Electrical Stimulation, Electroencephalography

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Aged 18-50 years of age
  2. Proficient in English
  3. Able to give informed consent
  4. Actively experiencing hallucinations (tactile, auditory, visual, etc.)
  5. Has not recently participated in tES/TMS treatments

Exclusion Criteria:

  1. Substance abuse or dependence (w/in past 6 months)
  2. Those who are pregnant/breastfeeding
  3. History of head injury with > 15 minutes of loss of consciousness/mal sequelae
  4. DSM-V intellectual disability
  5. Having a non-removable ferromagnetic metal within the body (particularly in the head)
  6. History of seizures

Sites / Locations

  • Beth Israel Deaconess Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Active Stimulation with TDCS

SHAM Stimulation

Arm Description

10 tDCS; Two, twenty-minute sessions of tDCS to the rSTS for 5 days (10 total sessions).

10 passive sham control; Two, twenty-minute sessions of passive sham control to the rSTS for a 30 second ramped up and down at the beginning and end of the 20 min period for 5 days (10 total sessions).

Outcomes

Primary Outcome Measures

Positive and Negative Syndrome Scale (PANSS)
Measuring total psychosis symptoms score (Total score minimum = 30, maximum = 210); General symptoms (minimum score = 16, maximum score = 112); Negative Symptoms (minimum score = 16, maximum score = 112); and Positive Symptoms (minimum score = 16, maximum score = 112); higher scores represent higher severity of symptoms
Positive and Negative Syndrome Scale (PANSS)
Measuring total psychosis symptoms score (Total score minimum = 30, maximum = 210); General symptoms (minimum score = 16, maximum score = 112); Negative Symptoms (minimum score = 16, maximum score = 112); and Positive Symptoms (minimum score = 16, maximum score = 112); higher scores represent higher severity of symptoms
University of Miami Parkinson's Disease Hallucinations Questionnaire (UM-PDHQ)
Measuring severity and duration of hallucinations; 20-item questionnaire to be used as a screening instrument to assess hallucinations (6 quantitative and 14 qualitative items); higher scores represent higher severity of symptoms
University of Miami Parkinson's Disease Hallucinations Questionnaire (UM-PDHQ)
Measuring severity and duration of hallucinations; 20-item questionnaire to be used as a screening instrument to assess hallucinations (6 quantitative and 14 qualitative items); higher scores represent higher severity of symptoms
7-item Auditory Hallucinations Rating Scale (AHRS)
Measuring severity and duration of hallucinations; severity for each item is rated on a 7-point scale; higher scores represent higher severity of symptoms
7-item Auditory Hallucinations Rating Scale (AHRS)
Measuring severity and duration of hallucinations; severity for each item is rated on a 7-point scale; higher scores represent higher severity of symptoms

Secondary Outcome Measures

Auditory Steady state evoked potential
Measuring the average evoked response potential amplitude change to an auditory stimulus
Auditory Steady state evoked potential
Measuring the average evoked response potential amplitude change to an auditory stimulus
Steady state visual evoked potential
Measuring the average evoked response potential amplitude change to a visual stimulus
Steady state visual evoked potential
Measuring the average evoked response potential amplitude change to a visual stimulus
Cross Modal Steady state evoked potential
Measuring the average evoked response potential amplitude change to a combined auditory and visual stimulus
Cross Modal Steady state evoked potential
Measuring the average evoked response potential amplitude change to a combined auditory and visual stimulus
Resting State EEG
Measuring neural activity at rest and connectivity
Resting State EEG
Measuring neural activity at rest and connectivity
Biological motion
Measuring the percent correct of detected motion by presenting a simulated walker; difficulty is increased by the level of random noise around stimuli
Biological motion
Measuring the percent correct of detected motion by presenting a simulated walker; difficulty is increased by the level of random noise around stimuli
Neurological Evaluation Scale; Sensory Integration
Measuring the percent correct of auditory and visual integration; auditory stimuli partners are matched to visual stimuli; difficulty is increased with more complex patterns
Neurological Evaluation Scale; Sensory Integration
Measuring the percent correct of auditory and visual integration; auditory stimuli partners are matched to visual stimuli; difficulty is increased with more complex patterns
Global assessment of function (GAF)
Measuring global functioning; severity of symptoms related to day-to-day life on a scale of 0 to 100; higher scores represent higher severity of symptoms
Global assessment of function (GAF)
Measuring global functioning; severity of symptoms related to day-to-day life on a scale of 0 to 100; higher scores represent higher severity of symptoms
Montgomery-Asberg Depression Rating Scale (MADRS)
Measuring total depression scores; 10 item scale related to depressive episodes (total score 0-60); higher scores represent higher severity of symptoms
Montgomery-Asberg Depression Rating Scale (MADRS)
Measuring total depression scores; 10 item scale related to depressive episodes (total score 0-60); higher scores represent higher severity of symptoms
Young Mania Rating Scale (YMRS)
Measuring total Mania scores; 11 items used to access severity of mania (total score 0-60); higher scores represent higher severity of symptoms
Young Mania Rating Scale (YMRS)
Measuring total Mania scores; 11 items used to access severity of mania (total score 0-60); higher scores represent higher severity of symptoms
Brief Assessment of Cognition (BACS)
Measuring cognition; cognitive domains assessed include memory, working memory, processing speed, executive functions and verbal fluency
Brief Assessment of Cognition (BACS)
Measuring cognition; cognitive domains assessed include memory, working memory, processing speed, executive functions and verbal fluency
Symptom Checklist-90
Measuring total psychiatric symptoms; 90 symptoms and evaluates nine symptomatic dimensions; higher scores represent higher severity of symptoms
Symptom Checklist-90
Measuring total psychiatric symptoms; 90 symptoms and evaluates nine symptomatic dimensions; higher scores represent higher severity of symptoms

Full Information

First Posted
November 17, 2021
Last Updated
December 19, 2022
Sponsor
Beth Israel Deaconess Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05165654
Brief Title
Improving Hallucinations by Targeting the rSTS With tES
Official Title
Improving Hallucinations by Targeting the Right Superior Temporal Sulcus With Electrical Stimulation
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2021 (Actual)
Primary Completion Date
October 1, 2024 (Anticipated)
Study Completion Date
November 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beth Israel Deaconess Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
Hallucinations are a core diagnostic feature of psychotic disorders. They involve different sensory modalities, including auditory, visual, olfactory, tactile, and gustatory hallucinations, among others. Hallucinations occur in multiple different neurological and psychiatric illnesses and can be refractory to existing treatments. Auditory hallucinations and visual hallucinations are found across diagnostic categories of psychotic disorders (schizophrenia, schizoaffective, bipolar disorder). Despite visual hallucinations being approximately half as frequent as auditory hallucinations, they almost always co-occur with auditory hallucinations, and are linked to a more severe psychopathological profile. Auditory and visual hallucinations at baseline also predict higher disability, risk of relapse and duration of psychosis after 1 and 2 years, especially when they occur in combination. Using a newly validated technique termed lesion network mapping, researchers demonstrated that focal brain lesions connected to the right superior temporal sulcus (rSTS) plays a causal role in the development of hallucinations. The rSTS receives convergent somatosensory, auditory, and visual inputs, and is regarded as a site for multimodal sensory integration. Here the investigators aim to answer the question whether noninvasive brain stimulation when optimally targeted to the rSTS can improve brain activity, sensory integration, and hallucinations.
Detailed Description
Functional neuroimaging studies have identified neural correlates of hallucinations across multiple brain regions. Some studies suggest a common neuroanatomical substrate independent of the sensory modality, while others suggest different neural correlates for different types of hallucinations. However, whether these neuroimaging findings represented a cause, consequence or epiphenomenon of hallucinations was unclear until recently. Using lesion network mapping, researchers demonstrated that focal brain lesions play a causal role in the development of hallucinations and can occur in different brain locations, both inside and outside sensory pathway, and that greater than 90% of lesion locations causing hallucinations are negatively connected to the right superior temporal sulcus (rSTS). The rSTS is known to play a role in social cognition, biological motion, audiovisual integration, and speech. Hence, when spontaneous activity decreases at lesion locations causing hallucinations, spontaneous activity in the rSTS increases, the exact pattern thought to predispose to hallucinations. Additionally, functional connectivity within this region is abnormal in patients with visual and auditory hallucinations. Therefore, the association between rSTS connectivity and hallucinations would suggest this region may be optimal for modulation via non-invasive brain stimulation. One method by which cortical excitability can be altered is with transcranial direct current stimulation (tDCS), a non-invasive brain stimulation technique. High definition tDCS (HD-tDCS) is a refined version of tDCS with improved spatial precision of cortical stimulation. This involves the application of a weak electrical current (1-2 mA) delivered to the brain via scalp electrodes. tDCS can modulate cortical excitability, where anodal stimulation tends to increase (i.e. the resting potential becomes less negative) and cathodal stimulation tends to decrease the underlying membrane potential (i.e. the resting potential becomes more negative). While tDCS is a promising adjunctive treatment of auditory hallucinations and negative symptoms in schizophrenia, less is known about its role in treating hallucinations overall. To date, no study has non-invasively stimulated the rSTS with tDCS in psychosis and examined its effects on hallucinations. However, there are studies in healthy volunteers showing that anodal stimulation to the STS resulted in increased auditory false perceptions, while cathodal stimulation decreased false perceptions and was lower than the sham condition. Taken together, the recent lesion network mapping identifying the rSTS as a major source of hallucinations combined with prior studies showing that the rSTS is associated with hallucinations suggest that it may be possible to alleviate hallucinations by designing a tDCS protocol that targets the rSTS with cathodal stimulation. Technological advances in noninvasive neuromodulation and electrical field modeling further allow us to create a tDCS protocol specifically guided by the results of lesion network mapping studies with high spatial resolution.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hallucinations, Auditory, Psychosis
Keywords
Transcranial Electrical Stimulation, Electroencephalography

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Masking Description
Double Blinded
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Active Stimulation with TDCS
Arm Type
Experimental
Arm Description
10 tDCS; Two, twenty-minute sessions of tDCS to the rSTS for 5 days (10 total sessions).
Arm Title
SHAM Stimulation
Arm Type
Sham Comparator
Arm Description
10 passive sham control; Two, twenty-minute sessions of passive sham control to the rSTS for a 30 second ramped up and down at the beginning and end of the 20 min period for 5 days (10 total sessions).
Intervention Type
Device
Intervention Name(s)
Transcranial Electrical Stimulation
Intervention Description
Transcranial electrical stimulation
Primary Outcome Measure Information:
Title
Positive and Negative Syndrome Scale (PANSS)
Description
Measuring total psychosis symptoms score (Total score minimum = 30, maximum = 210); General symptoms (minimum score = 16, maximum score = 112); Negative Symptoms (minimum score = 16, maximum score = 112); and Positive Symptoms (minimum score = 16, maximum score = 112); higher scores represent higher severity of symptoms
Time Frame
Change from baseline to day 5
Title
Positive and Negative Syndrome Scale (PANSS)
Description
Measuring total psychosis symptoms score (Total score minimum = 30, maximum = 210); General symptoms (minimum score = 16, maximum score = 112); Negative Symptoms (minimum score = 16, maximum score = 112); and Positive Symptoms (minimum score = 16, maximum score = 112); higher scores represent higher severity of symptoms
Time Frame
Change from baseline to month follow-up
Title
University of Miami Parkinson's Disease Hallucinations Questionnaire (UM-PDHQ)
Description
Measuring severity and duration of hallucinations; 20-item questionnaire to be used as a screening instrument to assess hallucinations (6 quantitative and 14 qualitative items); higher scores represent higher severity of symptoms
Time Frame
Change from baseline to day 5
Title
University of Miami Parkinson's Disease Hallucinations Questionnaire (UM-PDHQ)
Description
Measuring severity and duration of hallucinations; 20-item questionnaire to be used as a screening instrument to assess hallucinations (6 quantitative and 14 qualitative items); higher scores represent higher severity of symptoms
Time Frame
Change from baseline to month follow-up
Title
7-item Auditory Hallucinations Rating Scale (AHRS)
Description
Measuring severity and duration of hallucinations; severity for each item is rated on a 7-point scale; higher scores represent higher severity of symptoms
Time Frame
Change from baseline to day 5
Title
7-item Auditory Hallucinations Rating Scale (AHRS)
Description
Measuring severity and duration of hallucinations; severity for each item is rated on a 7-point scale; higher scores represent higher severity of symptoms
Time Frame
Change from baseline to month follow-up
Secondary Outcome Measure Information:
Title
Auditory Steady state evoked potential
Description
Measuring the average evoked response potential amplitude change to an auditory stimulus
Time Frame
Change from baseline to day 5
Title
Auditory Steady state evoked potential
Description
Measuring the average evoked response potential amplitude change to an auditory stimulus
Time Frame
Change from baseline to month follow-up
Title
Steady state visual evoked potential
Description
Measuring the average evoked response potential amplitude change to a visual stimulus
Time Frame
Change from baseline to day 5
Title
Steady state visual evoked potential
Description
Measuring the average evoked response potential amplitude change to a visual stimulus
Time Frame
Change from baseline to month follow-up
Title
Cross Modal Steady state evoked potential
Description
Measuring the average evoked response potential amplitude change to a combined auditory and visual stimulus
Time Frame
Change from baseline to day 5
Title
Cross Modal Steady state evoked potential
Description
Measuring the average evoked response potential amplitude change to a combined auditory and visual stimulus
Time Frame
Change from baseline to month follow-up
Title
Resting State EEG
Description
Measuring neural activity at rest and connectivity
Time Frame
Change from baseline to 5 day
Title
Resting State EEG
Description
Measuring neural activity at rest and connectivity
Time Frame
Change from baseline to month follow-up
Title
Biological motion
Description
Measuring the percent correct of detected motion by presenting a simulated walker; difficulty is increased by the level of random noise around stimuli
Time Frame
Change from baseline to 5 day
Title
Biological motion
Description
Measuring the percent correct of detected motion by presenting a simulated walker; difficulty is increased by the level of random noise around stimuli
Time Frame
Change from baseline to month follow-up
Title
Neurological Evaluation Scale; Sensory Integration
Description
Measuring the percent correct of auditory and visual integration; auditory stimuli partners are matched to visual stimuli; difficulty is increased with more complex patterns
Time Frame
Change from baseline to 5 day
Title
Neurological Evaluation Scale; Sensory Integration
Description
Measuring the percent correct of auditory and visual integration; auditory stimuli partners are matched to visual stimuli; difficulty is increased with more complex patterns
Time Frame
Change from baseline to month follow-up
Title
Global assessment of function (GAF)
Description
Measuring global functioning; severity of symptoms related to day-to-day life on a scale of 0 to 100; higher scores represent higher severity of symptoms
Time Frame
Change from baseline to day 5
Title
Global assessment of function (GAF)
Description
Measuring global functioning; severity of symptoms related to day-to-day life on a scale of 0 to 100; higher scores represent higher severity of symptoms
Time Frame
Change from baseline to month follow-up
Title
Montgomery-Asberg Depression Rating Scale (MADRS)
Description
Measuring total depression scores; 10 item scale related to depressive episodes (total score 0-60); higher scores represent higher severity of symptoms
Time Frame
Change from baseline to 5 day
Title
Montgomery-Asberg Depression Rating Scale (MADRS)
Description
Measuring total depression scores; 10 item scale related to depressive episodes (total score 0-60); higher scores represent higher severity of symptoms
Time Frame
Change from baseline to month follow-up
Title
Young Mania Rating Scale (YMRS)
Description
Measuring total Mania scores; 11 items used to access severity of mania (total score 0-60); higher scores represent higher severity of symptoms
Time Frame
Change from baseline to 5 day
Title
Young Mania Rating Scale (YMRS)
Description
Measuring total Mania scores; 11 items used to access severity of mania (total score 0-60); higher scores represent higher severity of symptoms
Time Frame
Change from baseline to month follow-up
Title
Brief Assessment of Cognition (BACS)
Description
Measuring cognition; cognitive domains assessed include memory, working memory, processing speed, executive functions and verbal fluency
Time Frame
Change from baseline to 5 day
Title
Brief Assessment of Cognition (BACS)
Description
Measuring cognition; cognitive domains assessed include memory, working memory, processing speed, executive functions and verbal fluency
Time Frame
Change from baseline to month follow-up
Title
Symptom Checklist-90
Description
Measuring total psychiatric symptoms; 90 symptoms and evaluates nine symptomatic dimensions; higher scores represent higher severity of symptoms
Time Frame
Change from baseline to 5 day
Title
Symptom Checklist-90
Description
Measuring total psychiatric symptoms; 90 symptoms and evaluates nine symptomatic dimensions; higher scores represent higher severity of symptoms
Time Frame
Change from baseline to month follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 18-50 years of age Proficient in English Able to give informed consent Actively experiencing hallucinations (tactile, auditory, visual, etc.) Has not recently participated in tES/TMS treatments Exclusion Criteria: Substance abuse or dependence (w/in past 6 months) Those who are pregnant/breastfeeding History of head injury with > 15 minutes of loss of consciousness/mal sequelae DSM-V intellectual disability Having a non-removable ferromagnetic metal within the body (particularly in the head) History of seizures
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Paulo Lizano, MD, PhD
Phone
(617) 754-1227
Email
plizano@bidmc.harvard.edu
Facility Information:
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paulo Lizano, MD, PhD
Phone
617-754-1227
Email
plizano@bidmc.harvard.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Improving Hallucinations by Targeting the rSTS With tES

We'll reach out to this number within 24 hrs